Med-Fine Capital focuses specifically on early-stage healthcare and biotech companies in China that are working to expand globally, backing frontier drug technologies like bispecific antibodies, ADCs, and T-cell engagers at their earliest stages, and adjusting its approach for different overseas markets rather than treating global expansion as one-size-fits-all. The firm also builds strategic ties beyond just China and the U.S., including connections in Southeast Asia, showing a broader regional network in healthcare investing.